Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Namwiwat Medical PCLBKK:NAM -0.60%39 EV-to-EBITDA is 11.50 as of Aug. 18, 2026, which is 5% below its 10-year median of 12.16. GuruFocus rates BKK:NAM with a GF Score™ of 39/100 and a GF Value™ of ฿5.89 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 513 Medical Devices & Instruments companies, Namwiwat Medical PCL ranks better than 62.57% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Namwiwat Medical PCL's enterprise value is ฿2,202 Mil.
Namwiwat Medical PCL's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ฿191 Mil. Therefore, Namwiwat Medical PCL's EV-to-EBITDA for today is 11.50.
The historical rank and industry rank for Namwiwat Medical PCL's EV-to-EBITDA or its related term are showing as below:
BKK:NAM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.13 Med: 12.16 Max: 60.06
Current: 11.5
During the past 6 years, the highest EV-to-EBITDA of Namwiwat Medical PCL was 60.06. The lowest was 7.13. And the median was 12.16.
BKK:NAM's EV-to-EBITDA is ranked better than 62.57% of 513
companies
in the Medical Devices & Instruments industry
Industry Median: 14.95
vs BKK:NAM: 11.50
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Namwiwat Medical PCL (BKK:NAM) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Namwiwat Medical PCL's PE Ratio (TTM) for today is calculated as:
Namwiwat Medical PCL's share price for today is ฿3.30.
Namwiwat Medical PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0.103.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Namwiwat Medical PCL's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Namwiwat Medical PCL's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Namwiwat Medical PCL EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Namwiwat Medical PCL's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Namwiwat Medical PCL's EV-to-EBITDA falls into.
Namwiwat Medical PCL's current Enterprise Value is ฿2,202 Mil.
Namwiwat Medical PCL's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿191 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Namwiwat Medical PCL (BKK:NAM) has a EV-to-EBITDA of 11.50 as of Aug. 18, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Namwiwat Medical PCL. This is near median its historical median of 12.16. Over the past decade, Namwiwat Medical PCL's EV-to-EBITDA has ranged from 7.13 to 60.06. According to the industry distribution chart, Namwiwat Medical PCL ranks #192 out of 513 companies in the Medical Devices & Instruments industry, placing it in the top 37.4%.
Is Namwiwat Medical PCL's EV-to-EBITDA too high?
Namwiwat Medical PCL's current EV-to-EBITDA of 11.50 is near median its 10-year median of 12.16. Over the past 10 years, this metric has ranged from a low of 7.13 to a high of 60.06. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.95. Namwiwat Medical PCL's value of 11.50 is 23.1% below this industry median. Based on the distribution chart, Namwiwat Medical PCL ranks #192 out of 513 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Namwiwat Medical PCL has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Namwiwat Medical PCL's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Namwiwat Medical PCL ranks #192 out of 513 companies for EV-to-EBITDA. This puts Namwiwat Medical PCL in the upper half of its industry. The industry median EV-to-EBITDA is 14.95. Namwiwat Medical PCL's value of 11.50 is 23.1% below this benchmark. Historically, Namwiwat Medical PCL's own EV-to-EBITDA has ranged from 7.13 to 60.06 over the past decade. While the company's 10-year median is 12.16 vs. the industry median of 14.95, Namwiwat Medical PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.95, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Namwiwat Medical PCL's current EV-to-EBITDA of 11.50 is 23.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Namwiwat Medical PCL. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Namwiwat Medical PCL's current EV-to-EBITDA is 11.50, which is near median its own 10-year median of 12.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Namwiwat Medical PCL stock overvalued right now?
Based on GuruFocus' analysis, Namwiwat Medical PCL (BKK:NAM) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿5.89, compared to a current price of ฿3.30 — trading 44% below its estimated fair value. The current EV-to-EBITDA is 11.50, which is near median its 10-year median of 12.16 and 23.1% below the Medical Devices & Instruments industry median of 14.95. Namwiwat Medical PCL's overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Namwiwat Medical PCL (BKK:NAM), the current EV-to-EBITDA is 11.50 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Namwiwat Medical PCL (BKK:NAM) Overvalued in 2026?
Based on GuruFocus' analysis, Namwiwat Medical PCL stock appears to be undervalued.
The current stock price of ฿3.30 is trading 44% below its estimated GF Value™ of ฿5.89.
GuruFocus considers Namwiwat Medical PCL to be Significantly Undervalued.
Key valuation signals for BKK:NAM:
EV-to-EBITDA: 11.50 (near median its 10-year median of 12.16)
GF Value™: ฿5.89 vs. price of ฿3.30 (44% below fair value)
Industry Position: 23.1% below the Medical Devices & Instruments median (#192 of 513)
No single metric tells the full story. See the BKK:NAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Namwiwat Medical Corp PCL operates a manufacturing business, importing and distributing Medical tools and equipment for cleaning and disinfecting medical equipment in hospitals and nursing homes in accordance with public health standards. The Group has a total of three reporting segments as follows: Medical equipment manufacturing and distribution segment; Medical supplies manufacturing and distribution segment; CSSD disinfection Medical equipment maintenance services segment, and waste services segment. The Group operates its business in one geography, only in Thailand.
39GF Score
Get the complete analysis for BKK:NAM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:NAM has been successfully added to your 
